Apple Turns 50: From Garage Startup to AI Crossroads 
Iran's Stranglehold on the Strait of Hormuz: What It Means for Global Markets 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Trump-Xi Summit 2026: U.S.-China Trade War Tensions and Tariff Talks 
U.S. Job Market Braces for Slow Recovery Amid Middle East Tensions and Economic Uncertainty 
Dollar Holds Steady as Yen Nears Critical 160 Level Amid Iran War Escalation 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
India's Central Bank Holds Rates Amid Iran War Energy Shock 
Gold Prices Drop as Trump Escalates Iran Threats, Oil Surges 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
March 2025 Jobs Report: Strong Headline Numbers Hide Deeper Economic Concerns 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Japan's Services Sector Growth Slows in March Amid Rising Middle East Tensions 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
U.S. Stock Futures Stabilize Ahead of Good Friday as Investors Eye Jobs Report 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SK Plasma Co. Ltd. is building a new blood product plant with an investment of KRW300 billion or about $250 million. The facility is set to be constructed in Indonesia.
Once in full operation, the new plant is expected to have the capacity to produce one million liters of blood products per year. SK Plasma will break ground some time this year, and the plant will be completed in two years.
Business insiders revealed earlier this week that the South Korean firm that produces albumin, immunoglobulin, coagulation factors, and antithrombin received the final approval for the construction of its plant from the Ministry of Health and Welfare of Indonesia not long ago. The facility will process the collected blood plasma and turn them into therapeutic agents.
Business Korea reported that for this project, SK Plasma would partner with Infion through a joint venture (JV) agreement. It is an Indonesian pharmaceutical company that will SK Plasma with its business operation in the country.
The size of the company’s upcoming plant in Indonesia is said to have a bigger production capacity than its facility in Andong, South Korea. It will offer 1.6 times more than the 600,000-liter capacity of its Korean plant.
In any case, the new factory will produce six types of blood products like Liv Gamma and albumin. The Korea Herald reported that albumin and immune globulin, which will be produced at the SK Plasma Indonesian facility, are typically used for patients with hemophilia and immunodeficiency diseases. These are made through strict and rigorous processes, including the centrifugation of blood collected from blood donation drives.
The blood products will ensure a stable supply in Indonesia, where the population is already close to 300 million. It was said that 100% of the citizens are currently dependent on imports of blood products.
“By transferring technologies relating to blood products and installing a manufacturing facility in a country that has no related infrastructure, SK Plasma seeks to create new business opportunities and reach the company’s ESG goals,” Kim Seung Joo, SK Plasma’s chief executive officer, said in a statement.
